Non-recovery of Kidney Function After AKI (RECOVER-AKI)

Non-recovery of Kidney Function After AKI: Identifying High Risk Groups and Assessment With Multiparametric Renal MRI

One in five patients admitted to hospital suffer a sudden reduction in kidney function, termed acute kidney injury (AKI). Rather than kidney 'injury' being caused by physical trauma, the term describes reversible damage caused by conditions such as being dehydrated or having an infection. Having AKI puts patients at an increased risk of long-term health problems, especially chronic kidney disease (CKD). CKD can also lead to other important health problems including a higher risk of heart disease and stroke. If we can reduce the progression of AKI to CKD this will benefit patients.

Currently, there is a gap in the follow-up of patients after AKI due to a lack of evidence about which patients should be followed up and when. Treatments for AKI during the episode and afterwards to prevent CKD are limited. This is mainly due to a lack of understanding about how and when the kidney recovers after AKI. New tools are needed in order to better identify patients at risk of CKD after AKI. This study aims to address these gaps in our knowledge by studying a group of AKI patients in detail.

Ultimately, the aim of this study is to produce results that will allow better planning of follow-up for patients as well the planning of future research to develop new treatments to reduce the risk of CKD in people recovering from AKI.

Study Overview

• Status: Not yet recruiting
• Conditions: Acute Kidney Injury
• Intervention / Treatment: Diagnostic test: Multiparametric renal MRI

Detailed Description

Acute kidney injury (AKI) is a sudden loss of renal function occurring in up to 20% of hospitalised patient. People who survive an episode of AKI are at increased risk of long-term effects on their health, in particular the development or progression of chronic kidney disease (CKD). At present, there are no interventions proven to reduce the development of CKD after an episode of AKI.

A significant gap exists in the current provision of post-AKI follow-up care. Current methods of assessing renal recovery are overly reliant on serum creatinine, an imperfect measure that over-estimate the degree of renal recovery due to the effect of critical illness on muscle mass. Based on expert opinion only, it is currently recommended that everyone who has experienced AKI should have kidney function and albuminuria checked at 90 days. In reality, current practice falls significantly below these standards. Less than half of patients with the most severe AKI see a nephrologist after discharge. Even for patients who have required dialysis for AKI, follow-up rates can be as low as 12%. Lack of evidence prevents a more evolved approach. Improving post-AKI care and reducing the development or progression of CKD could therefore directly benefit large numbers of patients. This is particularly pertinent with the additional restrictions on hospital appointments due to COVID-19. More evidence is urgently needed to inform which patients need follow-up and to integrate new techniques that significantly improve assessments of renal recovery.

Important knowledge gaps make it difficult to move directly to testing new interventions in randomised trials. AKI is not a single condition, rather a heterogeneous syndrome with a variety of causes affecting a wide range of people. Outcomes differ between clinical settings and are affected by factors related to AKI (e.g. its severity or duration), but also by an individual's co-existing long-term conditions, and possibly by their frailty. As well as CKD development, AKI is associated with higher long-term mortality rates, increased heart failure events, hospital readmissions, recurrent AKI and poorer quality of life. Which groups are most at risk of the different outcomes is not well established; similarly the groups that would have the greatest benefit from interventions to reduce the development of CKD are not currently known. It is therefore likely that subgroups of people who have sustained AKI will benefit from different models of post- AKI care i.e. a one-size fits all approach is unlikely to be beneficial or cost-effective. Finally, the timing of the renal recovery phase after an episode of AKI is poorly understood outside of experimental models, which differ in a number of ways from clinical AKI. Failure of recovery of creatinine by 90 days after AKI strongly associates with subsequent long-term reductions in renal function, suggesting that interventions may be needed prior to this time point, but descriptions of renal recovery between AKI and 90 days are lacking.

MRI has emerged as an imaging modality with promise to improve the understanding and characterisation of renal pathophysiology. It is a versatile technique in which structural and functional MRI measurements can be performed in a single multiparametric scan session to assess altered renal tissue microstructure, oxygenation, perfusion and blood flow. MRI is non-invasive, safe and avoids sampling bias by characterising the entire kidney with high spatial resolution. MRI does not involve ionising radiation, is repeatable (allowing serial assessments over time) and the MRI measures do not require gadolinium contrast agents. A series of recent systematic reviews covering the main functional renal MRI measures conclude that evidence is now needed to accelerate the translation of multiparametric renal MRI for clinical use. The reviews focussed on: arterial spin labelling (ASL, a measure of renal perfusion); Blood Oxygen Level Dependent (BOLD, sensitive to changes in renal oxygenation); longitudinal (T1) relaxation time (increases with scarring, correlates with fibrosis in the heart and liver; diffusion weighted imaging (DWI, sensitive to changes in renal tissue microstructure); and Phase Contrast (PC-MRI, a measure of renal artery blood flow).

Considering the high incidence of AKI, the long-term consequences of AKI present a major unmet clinical need affecting large numbers of people, with no proven interventions nor data to inform optimal care provision. If patients at risk of developing CKD could be better identified, this would provide a basis upon which interventions to improve patient outcomes could be planned.

The outputs of this study would directly inform planning of future research in the following ways:

• Collection of data supporting a larger prospective cohort study of AKI patients, using data from this study to directly inform study design and MRI protocols
• Identification of those at greatest risk of developing CKD after AKI will make clinical trials more efficient and more likely to succeed
• Increasing understanding of the time course of renal recovery will allow planning of the optimal time points for interventions and patient follow-up
• Demonstrate the potential application of renal MRI in NHS scanners leading to improved clinical evaluation of patients

• Study Type: Observational
• Enrollment (Anticipated): 50

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Hospital inpatients at Royal Derby Hospital across all areas.

Description

Inclusion Criteria:

• ≥18yrs
• Acute kidney injury stage 1-3 by KDIGO criteria
• At least one previous serum creatinine result available for determining baseline renal function
• Able to give informed consent

Exclusion Criteria:

• Unable to give consent or understand written information
• Obstructive uropathy
• Renal transplant
• Patient receiving palliative care
• Patient with AKI due to recent nephrectomy
• Patients with known or suspected acute vasculitis or glomerulonephritis requiring immunosuppression
• End-stage kidney disease (CKD stage G5 or already on RRT)
• Serum creatinine changes that do not meet the KDIGO definition of AKI

MRI cohort:

• Contraindications to MRI e.g. claustrophobia, cardiac pacemaker, metallic fragments or implants
• Age < 50years old

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of patients who have non-recovery of renal function after an episode of AKI	Defined as improvement of creatinine to less than 50% above baseline i.e. reversal of AKI diagnostic criteria	30, 60 and 90 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
90 day mortality	Day 90 data - based on status (alive/dead) at day 90	90 days
Hospital readmission rates	Number of times patients has been admitted to hospital based on hospital records	90 days
Quality of life score	Based on EQ5D (euroqol.org) scoring system. Descriptive scoring, lower number = higher quality of life	90 days
Fatigue score	Based on Brief Fatigue Inventory scoring (lower score = less fatigue)	90 days
Number of patients who have ongoing albuminuria over time	Progression / recovery over time. Urine albumin:creatinine ratio	Day 30,60 and 90
Descriptive analysis of preferred follow-up models	Based on structured questioning of participants	90 days
Change in renal structure over time	As measured by T1, total kidney volume & DWI	Day 30 & 90
Change in renal haemodynamics over time	As measured by ASL and phase-contrast MRI	Day 30 & 90
Change in renal oxygenation over time	As measured by TRUST MRI	Day 30 & 90

Collaborators and Investigators

• Sponsor: University of Nottingham

Study record dates

Study Major Dates

• Study Start (Anticipated): October 1, 2021
• Primary Completion (Anticipated): April 1, 2022
• Study Completion (Anticipated): April 1, 2022

Study Registration Dates

• First Submitted: August 4, 2021
• First Submitted That Met QC Criteria: August 12, 2021
• First Posted (Actual): August 20, 2021

Study Record Updates

• Last Update Posted (Actual): August 20, 2021
• Last Update Submitted That Met QC Criteria: August 12, 2021
• Last Verified: August 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Kidney Diseases; Urologic Diseases; Renal Insufficiency; Acute Kidney Injury
• Other Study ID Numbers: 21057; 302569 (Other Identifier: IRAS)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No